StockIQpro
NASDAQ:HRTX

Heron Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Heron Therapeutics, Inc.'s revenue grew 7.4% in fiscal 2025 to $154.9M while operating margin rose to −1.6%, its highest in 10 years. Free cash flow was −$27.9M, −18.0% of revenue, and the diluted share count rose 9.4%.Summary generated from Heron Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$154.9M
Revenue growth+7.4%
Revenue, 5-yr CAGR+11.8%
Gross margin73.3%
Operating margin−1.6%
Net margin−13.0%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$27.9M
FCF margin−18.0%
Share count change+9.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue86108127144155
Operating income−218−175−111−12−3
Net income−221−182−111−14−20
Free cash flow−206−149−60−24−28

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations